Viewing Study NCT00775359


Ignite Creation Date: 2025-12-24 @ 2:59 PM
Ignite Modification Date: 2026-01-01 @ 12:40 PM
Study NCT ID: NCT00775359
Status: COMPLETED
Last Update Posted: 2008-10-20
First Post: 2008-10-17
Is NOT Gene Therapy: True
Has Adverse Events: False

Brief Title: Bioequivalence Study of Fenofibrate 160mg Tablets Under Fed Conditions
Sponsor: Ranbaxy Laboratories Limited
Organization:

Study Overview

Official Title: Comparative, Randomized, Single-Dose, 2-Way Crossover Relative Bioavailability Study of Ranbaxy and Abbott (TriCorĀ®) 160 mg Fenofibrate Tablets in Healthy Adult Volunteers Under Fed Conditions
Status: COMPLETED
Status Verified Date: 2008-10
Last Known Status: None
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: None
Brief Summary: The objective of this study was to compare the single-dose relative bioavailability of Ranbaxy and Abbott (TriCor) 160 mg fenofibrate tablets under fed conditions.
Detailed Description: This was an open-label, randomized, single-dose, 2-way crossover, relative bioavailability study performed on 24 healthy adult male and female volunteers A total of 23 subjects (16 males and 7 females) completed the clinical phase of the study. In each period, subjects were housed from the evening before dosing until after the 24-hour blood draw. Subjects returned for all subsequent blood draws. Doses were separated by a washout period of 10 days.

Of the 24 healthy adult male and female volunteers enrolled in the study, 23 subjects (16 males and 7 females) completed the clinical phase of the study. Subject No. 10 failed to return for Period 2 check-in.

Study Oversight

Has Oversight DMC: True
Is a FDA Regulated Drug?: None
Is a FDA Regulated Device?: None
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: None
Is an FDA AA801 Violation?: